Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 63
Rev. bras. oftalmol ; 80(4): e0015, 2021. graf
Article in English | LILACS | ID: biblio-1288631


ABSTRACT The authors present a case of lupus miliaris disseminatus faciei , a rare skin disease of unknown etiology, which may cause unaesthetic scarring due to its difficult treatment. The histopathological examination of epithelioid granulomas with caseating necrosis, together with the clinical features, are important for diagnosis and early treatment with better results. Despite difficult and unsatisfactory treatment, there are ongoing studies on therapy to improve aesthetic and social impairment. This case report describes an initial misdiagnosis delaying appropriate treatment, and highlights the value of physical examination and clinical judgment for another pathological examination, whenever necessary, aiming at better treatment outcomes in daily practice.

RESUMO Os autores apresentam um caso de lupus miliaris disseminatus faciei , uma dermatose rara, de etiologia desconhecida, que pode deixar cicatrizes não estéticas, pela dificuldade de tratamento. O exame histopatológico de granulomas compostos por células epitelioides, com necrose caseosa, e as características clínicas, são importantes para o diagnóstico e tratamento precoce, com melhores resultados. Apesar do tratamento difícil e insatisfatório, há estudos em andamento sobre terapias para melhorar o comprometimento estético e social. Este relato de caso descreve um diagnóstico inicial errôneo, que atrasou o tratamento adequado, e destaca o valor do exame físico e raciocínio clínico para solicitar outro exame anatomopatológico, quando necessário, de forma a obter melhores desfechos com o tratamento, na prática diária.

Humans , Female , Adult , Eyelid Diseases/pathology , Eyelid Diseases/drug therapy , Facial Dermatoses/pathology , Facial Dermatoses/drug therapy , Tetracycline/therapeutic use , Prednisone/therapeutic use , Isotretinoin/therapeutic use , Cicatrix , Tacrolimus/therapeutic use , Rosacea/pathology , Rosacea/drug therapy , Dapsone/therapeutic use , Granuloma/pathology , Granuloma/drug therapy , Lupus Vulgaris/pathology , Lupus Vulgaris/drug therapy , Minocycline/therapeutic use
Article in English | WPRIM | ID: wpr-880607


Antipsychotic medication is the primary treatment for schizophrenia, which is effective on ameliorating positive symptoms and can reduce the risk of recurrence, but it has limited efficacy for negative symptoms and cognitive dysfunction. The negative symptoms and cognitive dysfunction seriously affects the life quality and social function for the patients with schizophrenia. Currently, there is plenty evidence that antipsychotic drugs combined with adjuvant therapy drugs can effectively improve the negative symptoms and cognitive dysfunction. These drugs include anti-oxidants, nicotinic acetylcholine receptors and neuro-inflammatory drugs (anti-inflammatory drugs, minocycline), which show potential clinical effects.

Anti-Inflammatory Agents/therapeutic use , Antipsychotic Agents/therapeutic use , Cognitive Dysfunction/etiology , Humans , Minocycline/therapeutic use , Schizophrenia/drug therapy
Evid. odontol. clín ; 4(2): 21-30, jul.-dic. 2018. ilus, tab, graf
Article in Spanish | LILACS | ID: biblio-995395


La investigación está orientada a buscar medidas más directas para tratar el problema de la proliferación bacteriana, durante el tratamiento de bolsa, favoreciendo una rápida curación en un medio libre de bacterias. Objetivos: Determinar el Chip que tenga mejor efecto en la proliferación bacteriana de la microflora de bolsas periodontales. Material y métodos: Los grupos fueron constituidos 2 grupos experimentales de chip de tetraciclina y de minociclina y un grupo control con disco de tetraciclina y un blanco, las bacterias fueron obtenidas de 16 pacientes, estas se suspendieron en Caldo peptopnado dejándose en la incubadora por 24 horas y después se sembraron en las placas Petri conteniendo Agar sangre.. La información obtenida se recopiló en Fichas de observación microbiológica a las 24, 48 y 72 horas. El estudio realizado fue de tipo experimental, prospectiva, longitudinal y el nivel de investigación fue experimental. Se utilizó el software SPSS versión 21. El análisis que se realizó se dio por la variable independiente bifactorial(chip de tetraciclina y chip de minociclina)y por la variable dependiente univariado, así mismo por la naturaleza de la investigación va a ser un análisis cuantitativo. Resultados: Los resultados obtenidos muestran un efecto inhibiendo la proliferación bacteriana de la microflora de bolsas periodontales, que se manifestaron por la presencia de halos de inhibición en las diferentes con una media de 11,94 a las 72 horas correspondiente al chip de tetraciclina y un promedio de 6.25 milímetros a las 72 horas del chip de minociclina, obteniéndose un valor de p = 0.000, es decir p <0.005. Conclusiones: El chip de minociclina presenta una acción menor que el de la tetraciclina, negando la hipótesis planteada, es decir existe diferencia estadística entre ambos. (AU)

The research is oriented to seek more direct measures to treat the problem of bacterial proliferation, during bag treatment, favoring a quick cure in a bacteria-free environment. Objectives: Determine the Chip that has the best effect on the bacterial proliferation of periodontal pocket microflora. Material and Methods: The groups were constituted 2 experimental groups of tetracycline chip and minocycline and a control group with tetracycline disc and a white, the bacteria were obtained from 16 patients, these were suspended in broth peptopnado leaving in the incubator for 24 hours and then they planted in the Petri dishes containing blood agar. The information obtained was compiled in microbiological observation sheets at 24, 48 and 72 hours. The study was experimental, prospective, longitudinal and the level of research was experimental. The software SPSS version 21 was used. The analysis was carried out by the independent variable bifactorial (chip of tetracycline and chip of minocycline) and by the univariate dependent variable, likewise by the nature of the research it will be a quantitative analysis. Results: The results obtained show an effect inhibiting the bacterial proliferation of the periodontal pocket microflora, which was manifested by the presence of inhibition halos in the different ones with a mean of 11.94 at 72 hours corresponding to the tetracycline chip and an average of 6.25 millimeters at 72 hours of the minocycline chip, obtaining a value of p = 0.000, that is p <0.005. Conclusions: Finally we conclude that the l chip of minocycline has a lower action than that of tetracycline, denying the hypothesis, that is, there is a statistical difference between the two. (AU)

Periodontal Pocket , Tetracycline , Minocycline/therapeutic use
Medical Journal of Tabriz University of Medical Sciences and Health Services. 2017; 39 (1): 78-85
in Persian | IMEMR | ID: emr-188658


Background: Pseudomonas aeruginosa is a gram negative bacillus. Infection with these bacteria usually occur! in patients who hospitalized due to: need for prolonged stay in ICU, those who have intravascular catheters, or indwelling urinary catheters

This Study investigates in vitro susceptibility of pseudomonas aeruginosa which were isolated from patients with UTI to doxycycline, tigecycline, ceftazidime, cefepime, piperacillin/tazobactam, impipenem, meropenem, colistin, ciprofloxacin, nitrofurantoin, amikacin] with standard disk diffusion. Comparing the, susceptibility results of disk diffusion with E.test for doxycycline and tigecycline is another aim. Other purpose of this study was to define MDR pseudomonas aeruginosa susceptibility to doxycycline and tigecycline

Methods: Sixty pseudomonas aeruginosa which was isolated after biochemical and bacteriological test, were entered to study and susceptibility to above antibiotics was tested by disk diffusion. For doxycycline and tigecycline antibiogram by two methods were performed: disk diffusion and Etest

Result: Maximum susceptibility was observed for colistin =95% followed by sensitivity in decreasing order for these antibiotics .Meropenem 76% Imipenem= Cefepime

Conclusion: In vitro susceptibility of isolated pseudomonas aeruginosa to studied antibiotics [with exception of colistin] was less than 80% even for carbapenems

Disk diffusion for doxycycline and tigecycline wasn't effective for differentiation intermediate resistance from sensitive. Calculation of cohens Kappa for agreement was moderate. Most of MDR pseudomonas aeruginosa was resistant to doxycycline and tigecycline

Humans , Urinary Tract Infections/microbiology , Doxycycline/therapeutic use , Minocycline/therapeutic use , Disk Diffusion Antimicrobial Tests , In Vitro Techniques
Rev. méd. Chile ; 144(9): 1214-1217, set. 2016. ilus
Article in Spanish | LILACS | ID: biblio-830630


Pityriasis lichenoides et varioliformis acuta (PLEVA), pityriasis lichenoides chronica (PLC) and febrile ulceronecrotic Mucha-Habermann disease (FUMHD) are considered different manifestations of the same disease. Febrile ulceronecrotic Mucha-Habermann disease is a rare, and potentially lethal illness which is characterized by fast progression of numerous papules that converge, ulcerate and form a plaque with a necrotic center, together with hemorrhagic vesicles and pustules that are associated with high fever and variable systemic symptoms. We report a 16 years old male presenting with erythematous papules with crusts and fever. The diagnosis of febrile ulceronecrotic Mucha-Habermann disease was confirmed with the pathological study of the lesions. He was successfully treated with minocycline after a failed attempt of treatment with prednisone.

Humans , Male , Adolescent , Prednisone/therapeutic use , Pityriasis Lichenoides/drug therapy , Herpes Simplex/drug therapy , Anti-Inflammatory Agents/therapeutic use , Minocycline/therapeutic use , Skin Ulcer/pathology , Treatment Outcome , Pityriasis Lichenoides/pathology , Herpes Simplex/pathology
Braz. j. infect. dis ; 20(3): 272-275, May.-June 2016. tab
Article in English | LILACS | ID: lil-789475


Abstract Treatment of orthopedic infections usually requires prolonged antimicrobial therapy, ranging from 14 days up to 6 months. Nowadays, rising levels of antimicrobial resistance demands parenteral therapy for many patients. Outpatient parenteral antimicrobial therapy (OPAT) is a modality that allows treatment out of hospital in these situations. In Brazil, where a public universal healthcare system allows full coverage for all citizens, implantation and dissemination of OPAT programs would be beneficial for patients and for the system, because it would allow a better allocation of health resources. The Instituto de Ortopedia e Traumatologia do Hospital das Clínicas da Faculdade de Medicina da USP (IOT) started, in July 2013, a partnership with municipal health authorities in Sao Paulo, Brazil, in order to initiate an OPAT program in which patients discharged from that hospital would be able to continue antimicrobial therapy at primary care facilities. When necessary, patients could also receive their therapy at the day-hospital located at IOT. Primary care nursing and physician staff were trained about antimicrobial infusion and peripherally inserted central catheter manipulation. An OPAT specific antimicrobial protocol was designed and a special reference and counter-reference organized. As a result, 450 primary healthcare professionals were trained. In the first year of this program, 116 patients were discharged for OPAT. Chronic and acute osteomyelitis were most frequent diagnosis. Teicoplanin, ertapenem and tigecycline were the most used drugs. Duration of treatment varied from 10 to 180 days (average 101, median 42). Total sum of days in OPAT regimen was 11,698. Only 3 patients presented adverse effects. Partnership between services of different levels of complexity allowed implantation of a safe and effective public healthcare OPAT program for treatment of orthopedic infections. This program can serve as a model for developing similar strategies in other regions of Brazil and Latin America.

Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Aged , Young Adult , Osteomyelitis/therapy , beta-Lactams/therapeutic use , Infusions, Parenteral/methods , Minocycline/analogs & derivatives , Anti-Bacterial Agents/administration & dosage , Outpatients , Bone Diseases, Infectious/classification , Bone Diseases, Infectious/drug therapy , Brazil , Ertapenem , Tigecycline , Anti-Infective Agents , Minocycline/therapeutic use , Anti-Bacterial Agents/classification
Arch. argent. pediatr ; 114(2): e78-e83, abr. 2016. ilus, graf
Article in Spanish | LILACS, BINACIS | ID: biblio-838187


El pseudotumor cerebral se caracteriza por una elevación de la presión intracraneal mayor de 20 cmH2O, con ventrículos y líquido cefalorraquídeo de características normales. El consumo de minociclina es una de las causas asociadas a este síndrome. Presentamos una paciente de 13 años de edad con antecedentes de acné tratado con minociclina. Comenzó con cefalea intensa, diplopía y visión borrosa. Se constató el diagnóstico de pseudotumor cerebral y se indicó la suspensión inmediata del antibiótico y el inicio del tratamiento con acetazolamida. Aunque la patogénesis de pseudotumor cerebral no es totalmente conocida, se ha observado una asociación con el empleo de minociclina. Este antibiótico es de uso frecuente para el manejo del acné, por lo que es importante considerar sus complicaciones antes de ser prescrito.

Pseudotumor cerebri is a syndrome characterized by an elevated intracranial pressure greater than 20 cmH2O with ventricles and cerebrospinal fluid of normal characteristics. Consumption of minocycline have been described among the causes associated with this syndrome. We present a 13-year old female patient with a history of acne treated with minocycline who began with severe headache, diplopia and blurred vision. The diagnosis of pseudotumor cerebri was made, indicating the immediate antibiotic suspension and the beginning of the treatment with acetazolamide. Although the pathogenesis of pseudotumor cerebri is not fully known, an association with minocycline has been observed. This antibiotic is often used by health professionals for the management of acne, so it is important to consider its complications before being prescribed.

Humans , Female , Adolescent , Pseudotumor Cerebri/diagnosis , Pseudotumor Cerebri/chemically induced , Acne Vulgaris/drug therapy , Minocycline/adverse effects , Minocycline/therapeutic use , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/therapeutic use
Article in English | IMSEAR | ID: sea-159447


Pyoderma gangrenosum is a rare, ulcerative, non-infectious neutrophilic dermatosis, commonly associated with underlying systemic disease. The features of pyoderma gangrenosum are not specific histopathologically and for this reason the diagnosis is based on clinical feature. The systemic administration of corticosteroids is the mainstay of treatment. We present five cases of pyoderma gangrenosum of age group ranging from 2 to 75 years. One of these patients was HIV-infected, and one was having discoid lupus erythematosus. The lesions were present on thighs in 3 cases, over back in one and breast in one. Biopsy showed central necrosis with multiple neutrophilic abscesses in epidermis. The dermis showed dense neutrophilic infiltration in both superficial and deep dermis. The lesions responded well to oral corticosteroids except in the case of HIV-infected patient in which minocycline showed considerable improvement.

Adolescent , Adult , Aged , Child, Preschool , Female , HIV Infections/complications , Humans , Middle Aged , Minocycline/administration & dosage , Male , Minocycline/therapeutic use , Prednisolone/administration & dosage , Prednisolone/therapeutic use , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/pathology
Acta odontol. latinoam ; 28(2): 122-131, 2015. ilus, tab
Article in English | LILACS | ID: lil-768615


El objetivo de este estudio fue evaluar el efecto clínico y microbiológico de microgránulos de Minociclina, colocados subgingivalmente como coadyuvante del raspaje y alisado radicular en pacientes con Periodontitis crónica severa. Participaron 26 sujetos voluntarios con Periodontitis crónica, no fumadores. Se seleccionaron 4 sitios contralaterales con Sangrado al Sondaje (SS) y Profundidad al Sondaje (PS) > 6 mm. Condición Basal (CB): se registró, PS y Nivel de Inserción (NI). Se determinó mdiante PCR la presencia de Porphyromonas gingivalis (Pg), Tannerella forsythia (Tf), Treponema denticola (Td) y Aggregatibacter actinomycetemcomitans (Aa). Un lado de la boca fue aleatoriamente asignado al tratamiento experimental: grupo T, el otro al tratamiento control: grupo C. Al día 30 y 90 se repitieron los exámenes clínicos y microbiológicos. Día 30: el SS se redujo al 81 por ciento en el grupo C y al 12 por ciento en el grupo T (p<0,05). Estas diferencias se mantuvieron al día 90 (C: 58 por ciento, T: 8 por ciento) (p<0.05). Día 30 y 90: hubo disminución de la PS en ambos grupos, siendo significativamente mayor en el grupo T (p<0,05). En ambos grupos hubo disminución significativa del NI (p<0,05), no hubo diferencias entre los grupos al día 30 y sí al día 90. A los 30 y 90 días en ambos grupos se redujo la prevalencia para Pg, Tf ,Td y Aa. A los 30 y 90 días la reducción de sitios con Pg fue mayor en el grupo T (p=0,002). A los 90 días Td disminuyó en el grupo T y aumentó en el grupo C (p=0,023). No se observaron efectos adversos. Los resultados mostraron que la aplicación subgingival de microgránulos de minociclina adjunta al raspaje y alisado radicular produjo una reducción mayor del SS, la PS y el NI que el raspaje y alisado solo, aumentó la probabilidad de suprimir Pg y retardó la recolonización con Td.

The aim of this study was to evaluate clinical and microbiological effects of subgingival minocycline microgranules when used as an adjunct to scaling and root planing in subjects with Chronic periodontitis. Twenty-six non-smoker volunteers participated in the study. Four opposite sites, clinically standardized, with bleeding on probing (BOP) and pocket depth (PD) ≥ 6 mm were selected. Baseline BOP, PD and Clinical attachment level (CAL) were measured and microbiological samples were collected from the study sites and analyzed using PCR. Porphyromonas gingivalis (Pg) Tannerella forsythia (Tf), Treponema denticola (Td) and Aggregatibacter actinomycetemcomitans (Aa) were detected. One side of the mouth was randomly allocated to the experimental treatment: scaling and root planing plus minocycline microgranules (Test group=T) and the other side of the mouth toscaling and root planing alone (Control group=C). At days 30 and 90, clinical and microbiological examination was repeated. After 30 days BOP was reduced to 81% in C and to 12% in T and at day 90 to 58% in C and to 8% in T (p<0.05). PD wassignificantly reduced in both groups (C: 4.8mm, T: 4.2mm) favoring T at days 30 and 90 (p<0.05). CAL reduction at day 30 showed no difference between groups. At day 90, CAL reduction was higher in T (p<0.05). At days 30 and 90 Pg, Tf, Td and Aa was reduced in both groups. Pg reduction wassignificantly greater in group T. At day 90 frequency of sites with Td decreased in T and increased in C (p<0.05). No adverse effect was observed. This study showed that minocycline microgranules adjunct to scaling and root planing resulted in grater reduction of BOP and PD, higher CAL gain, increased probability of Pg suppression and retarded recolonization of Td than root instrumentation alone.

Humans , Male , Female , Adult , Minocycline/therapeutic use , Chronic Periodontitis/microbiology , Chronic Periodontitis/drug therapy , Dental Scaling/methods , Administration, Topical , Analysis of Variance , Argentina , Aggregatibacter actinomycetemcomitans/isolation & purification , Schools, Dental , Microbiological Techniques , Porphyromonas gingivalis/isolation & purification , Polymerase Chain Reaction/methods , Statistical Analysis , Treponema denticola/isolation & purification
Indian J Dermatol Venereol Leprol ; 2014 Jan-Feb; 80(1): 29-35
Article in English | IMSEAR | ID: sea-154740


Background: Oral minocycline has been recently shown to halt disease progression in active vitiligo. Aims: The present study was planned to compare the efficacy and tolerability of oral minocycline with oral mini pulse (OMP) corticosteroids in active vitiligo. Methods: A total of 50 patients with actively spreading vitiligo were randomized to receive either minocycline 100 mg/day (Group I - 25 patients) or OMP 2.5 mg dexamethasone on 2 consecutive days in a week (Group II - 25 patients) for 6 months. These were followed-up at every 2 weeks interval. Mean vitiligo disease activity score (VIDA) and mean Vitiligo Area Scoring Index (VASI) were assessed in all patients in addition to the photographic comparison before and after treatment. Results: Both groups showed a significant decrease in VIDA from 4.0 to 1.64 ± 0.86 (P < 0.001) in Group I and from 4.0 to 1.68 ± 0.69 (P < 0.001) in Group II. However, the difference between the mean VIDA scores in the two groups was not statistically significant (P = 0.60) at the end of treatment period. The mean VASI declined from 1.71 ± 1.45 to 1.52 ± 1.43 Group I (P = 0.06) and from 1.39 ± 1.31 to 1.17 ± 1.34 in Group II (P = 0.05). The difference between VASI in Group I and II was not significant at the end of 24 weeks of treatment (P = 0.11). Conclusion: Both dexamethasone OMP and oral minocycline are effective drugs for managing the arrest of disease activity in vitiligo.

Adolescent , Adult , Administration, Oral , Dexamethasone/administration & dosage , Dexamethasone/therapeutic use , Female , Humans , Male , Middle Aged , Minocycline/administration & dosage , Minocycline/therapeutic use , Pulse Therapy, Drug/methods , Randomized Controlled Trials as Topic , Vitiligo/drug therapy , Young Adult
Rev. chil. infectol ; 30(6): 591-597, dic. 2013. ilus, tab
Article in Spanish | LILACS | ID: lil-701704


Background: Tigecycline is indicated for the treatment of complicated skin infections, soft tissue and intraabdominal infections. Its use could be extended to community-acquired pneumonia (CAP) and hospital pneumonia (HN). The objective was to evaluate the efficacy and safety of tigecycline in the treatment of respiratory infections. Methods: systematic review (2012). Databases used were MEDLINE, EMBASE, Cochrane Library, CRD and WOK. We identified clinical trials of adults with respiratory infection, treated with tigecycline. The quality of the studies was assessed using CASPe checklist. Results: We selected four clinical trials of high-moderate quality. Three studies with patients with CAP and a trial with HN patients. In patients with CAP, efficacy of tigecycline (88.6 to 90.6%) was higher than levofloxacin (85.3 to 87.2%). The non inferiority testing was statistically significant (p < 0.001). In the study of patients with HN tigecycline showed an efficiency of 67.9% versus 78.2% for imipenem/cilastatin. Main adverse effects were gastrointestinal. Conclusions: The efficacy of tigecycline is non inferior than levofloxacin in patients with CAP, but less than imipenem in patients with HN. Tigecycline demonstrates noninferiority versus others tested antibiotics, and it shows a good safety profile.

Introducción: Tigeciclina está indicada en el tratamiento de infecciones complicadas de piel, tejidos blandos e intra-abdominales. Su utilización podría extenderse para neumonías adquiridas en la comunidad (NAC) y neumonías hospitalarias (NH). El objetivo ha sido evaluar la eficacia y seguridad de tigeciclina en el tratamiento de infecciones respiratorias. Material y Métodos: Revisión sistemática (2012). Se realizaron búsquedas en MedLine, Embase, Cochrane Library, CRD y WOK. Se localizaron ensayos clínicos de adultos con infección respiratoria, tratados mediante tigeciclina. La calidad de los estudios se valoró mediante los criterios CASPe. Resultados: Se seleccionaron cuatro ensayos clínicos de calidad alta-moderada. Tres estudios incluyeron pacientes con NAC y un estudio a pacientes con NH. En pacientes con NAC la eficacia de tigeciclina (88,6-90,6%) fue no inferior a la de levofloxacina (85,3-87,2%). El "test de no inferioridad" fue estadísticamente significativo (p < 0,001). En el estudio de pacientes con NH, tigeciclina presentó una eficacia de 67,9% frente a 78,2% de imipenem/cilastatina. Los principales efectos adversos fueron gastrointestinales. Conclusiones: la eficacia de tigeciclina es no inferior a la de levofloxacina en pacientes con NAC, pero inferior a imipenem en pacientes con NH. Tigeciclina ha demostrado no inferioridad frente a los otros antimicrobianos testados. Tigeciclina demuestra tener un buen perfil de seguridad.

Adult , Humans , Anti-Bacterial Agents/therapeutic use , Cross Infection/drug therapy , Minocycline/analogs & derivatives , Pneumonia/drug therapy , Anti-Bacterial Agents/adverse effects , Clinical Trials as Topic , Community-Acquired Infections/drug therapy , Minocycline/adverse effects , Minocycline/therapeutic use , Respiratory Tract Infections/drug therapy
Rev. chil. infectol ; 29(3): 317-321, jun. 2012. tab
Article in Spanish | LILACS | ID: lil-645598


Introduction: Infections produced by multidrug-resistant pathogens represent a therapeutic challenge because of the few therapeutic options available. Tigecycline is a relatively new antibiotic, with a wide spectrum of activity including some of these resistant bacteria. In adults is prescribed for the treatment of some infections caused by carbapenem resistant K. pneumoniae, however it has not been approved in children because of potential adverse effects in the dental enamel. Materials and Methods: Case series study. Medical records were reviewed in all children from 0 to 14 years of age that received tigecycline between January of 2008 and March of 2010. Results: 9 patients received Tigecycline mainly for treatment of peritonitis, bacteremia, pneumonia and sepsis caused by carbapenem resistant K. pneumoniae. A dose of 1 mg/kg q 12 hours was administered to all patients. No adverse events were reported and a total of 6 patients had complete resolution of the infection. Conclusions: Tigecycline could be considered a therapeutic option for treating infections produced by multidrug-resistant pathogens in children. The use in children is still compassionate and in this serie of cases Tigecycline was well tolerated and safe.

Introducción: Las infecciones causadas por bacterias multi-resistentes son difíciles de tratar debido a las pocas opciones terapéuticas disponibles. Tigeciclina es un antimicrobiano relativamente nuevo que tiene un amplio espectro de acción, incluyendo algunas de estas bacterias. En adultos se utiliza para el tratamiento de algunas infecciones producidas por Klebsiella pneumoniae productora de carbapenemasas (Kpn KPC). Sin embargo, por pertenecer al grupo de las tetraciclinas, su uso no ha sido aprobado en niños temiendo los posibles efectos adversos sobre el esmalte dental. Material y Métodos: Estudio de serie de casos. Se realizó una revisión de las historias clínicas de todos los niños de 0 a 14 años que recibieron tigeciclina en forma compasiva entre enero de 2008 y marzo de 2010. Resultados: 9 pacientes recibieron tigeciclina para tratamiento de peritonitis, bacteriemia, neumonía y sepsis por Kpn KPC. La dosis utilizada fue de 1 mg/kg/dosis cada 12 horas. No se encontraron efectos adversos importantes. La infección se consideró curada en 6 pacientes. Conclusiones: Tigeciclina puede ser considerada como una alternativa en el tratamiento de infecciones por bacterias multi-resistentes en niños. Su uso en la edad pediátrica sigue siendo compasivo y en esta serie de casos fue seguro.

Child, Preschool , Female , Humans , Infant , Male , Anti-Bacterial Agents/therapeutic use , Carbapenems/therapeutic use , Compassionate Use Trials/methods , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/drug effects , Minocycline/analogs & derivatives , Fatal Outcome , Klebsiella Infections/microbiology , Minocycline/therapeutic use , Retrospective Studies , beta-Lactam Resistance/drug effects
Dermatol. peru ; 21(4): 158-162, oct.-dic. 2011. ilus
Article in Spanish | LIPECS, LILACS, LIPECS | ID: lil-671779


La papilomatosis reticulada y confluente es una dermatosis ictiosiforme crónica y recurrente que se observa en adultos jóvenes; afecta más a mujeres que a hombres. Se caracteriza por la presencia de máculas, pápulas, parches y placas escamosas colorpardo localizadas en cuello, región intermamaria, interescapular y axilas. El tratamiento resulta frustante pues ningún fármacoha dado bueno resultados a largo plazo. La minociclina es uno de los antibióticos con el que más éxito se ha obtenido. Se reportan tres casos de mujeres jóvenes con buena respuesta a la administración de este fármaco. Se presentan estos casos por ser una entidad de difícil tratamiento.

Confluent and reticulated papillomatosis is a chronic andrecurrent ichthyosiform dermatoses observed in young adults, affecting more women than men. It is characterized by the presence of macules, papules, patches and brown scaly plaqueslocated in the neck, intermamaria and interscapular region andarmpits. Treatment is frustrating because no drug has givengood long-term results. Minocycline is an antibiotic of the most successful has been obtained. We report three cases of young women with good response to the administration of the drug. Wepresent these cases as an entity of difficult treatment.

Humans , Adolescent , Female , Young Adult , Acanthosis Nigricans , Ichthyosis , Medical Illustration , Minocycline/therapeutic use , Papilloma , Case Reports
Article in English | IMSEAR | ID: sea-135679


Repurposing of old drugs is a useful concept as it helps to minimize costs associated with the research and development of a new drug. Minocycline, a common second generation antibiotic, has been shown to possess several other beneficial effects other than its intended uses. The antiviral role of minocycline has generated considerable interest from the last decade. It was first shown to be beneficial in preventing human immunodeficiency virus (HIV) infections and later it was reported to improve cognitive deficiencies associate with neuroAIDS. However, its antiviral efficacies are not limited to retroviruses alone. In animal models or in vitro systems of flaviviral infections (especially Japanese encephalitis virus), minocycline has been shown to be highly effective. However, not all effects are based on direct inhibition of viral replication. The general anti-inflammatory and immunomodulatory properties of minocycline are also responsible in part, in imparting the protective effects. Owing to the fact that minocycline is well tolerated by most people and that the drug has nearly 40 years history of usage, it is an exciting prospect to try out in other viral infections.

Anti-Inflammatory Agents/therapeutic use , Antiviral Agents/therapeutic use , Humans , Immunologic Factors/therapeutic use , Minocycline/therapeutic use , Virus Diseases/drug therapy , Virus Diseases/immunology